PMC:7228307 / 53201-53475 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1090","span":{"begin":254,"end":258},"obj":"Gene"},{"id":"1091","span":{"begin":53,"end":57},"obj":"Gene"},{"id":"1094","span":{"begin":14,"end":40},"obj":"Disease"},{"id":"1095","span":{"begin":169,"end":174},"obj":"Mutation"},{"id":"1096","span":{"begin":176,"end":181},"obj":"Mutation"},{"id":"1097","span":{"begin":183,"end":188},"obj":"Mutation"},{"id":"1098","span":{"begin":216,"end":221},"obj":"Mutation"}],"attributes":[{"id":"A1090","pred":"tao:has_database_id","subj":"1090","obj":"Gene:2213"},{"id":"A1091","pred":"tao:has_database_id","subj":"1091","obj":"Gene:2213"},{"id":"A1094","pred":"tao:has_database_id","subj":"1094","obj":"MESH:D010300"},{"id":"A1095","pred":"tao:has_standard_notation","subj":"1095","obj":"p.E233P"},{"id":"A1096","pred":"tao:has_standard_notation","subj":"1096","obj":"rs755807976"},{"id":"A1097","pred":"tao:has_standard_notation","subj":"1097","obj":"p.L235A"},{"id":"A1098","pred":"tao:has_standard_notation","subj":"1098","obj":"p.D265A"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The IgG4 anti‐PD‐1 antibody tislelizumab has had its FcγR contact residues in the lower hinge E233, F234, L235 substituted with the equivalent residues of IgG2 P, V, A (E233P, F234V, L235A) as well as the additional D265A mutation which disrupts a major FcγR contact in CH2."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T409","span":{"begin":19,"end":27},"obj":"Body_part"}],"attributes":[{"id":"A409","pred":"fma_id","subj":"T409","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"The IgG4 anti‐PD‐1 antibody tislelizumab has had its FcγR contact residues in the lower hinge E233, F234, L235 substituted with the equivalent residues of IgG2 P, V, A (E233P, F234V, L235A) as well as the additional D265A mutation which disrupts a major FcγR contact in CH2."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T898","span":{"begin":41,"end":44},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T899","span":{"begin":53,"end":55},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T900","span":{"begin":106,"end":110},"obj":"http://purl.obolibrary.org/obo/CLO_0007179"},{"id":"T901","span":{"begin":166,"end":167},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T902","span":{"begin":246,"end":247},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T903","span":{"begin":254,"end":256},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"}],"text":"The IgG4 anti‐PD‐1 antibody tislelizumab has had its FcγR contact residues in the lower hinge E233, F234, L235 substituted with the equivalent residues of IgG2 P, V, A (E233P, F234V, L235A) as well as the additional D265A mutation which disrupts a major FcγR contact in CH2."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T85014","span":{"begin":14,"end":16},"obj":"Chemical"}],"attributes":[{"id":"A84471","pred":"chebi_id","subj":"T85014","obj":"http://purl.obolibrary.org/obo/CHEBI_74756"}],"text":"The IgG4 anti‐PD‐1 antibody tislelizumab has had its FcγR contact residues in the lower hinge E233, F234, L235 substituted with the equivalent residues of IgG2 P, V, A (E233P, F234V, L235A) as well as the additional D265A mutation which disrupts a major FcγR contact in CH2."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"1090","span":{"begin":254,"end":258},"obj":"Gene"},{"id":"1091","span":{"begin":53,"end":57},"obj":"Gene"},{"id":"1094","span":{"begin":14,"end":40},"obj":"Disease"},{"id":"1095","span":{"begin":169,"end":174},"obj":"Mutation"},{"id":"1096","span":{"begin":176,"end":181},"obj":"Mutation"},{"id":"1097","span":{"begin":183,"end":188},"obj":"Mutation"},{"id":"1098","span":{"begin":216,"end":221},"obj":"Mutation"}],"attributes":[{"id":"A1090","pred":"pubann:denotes","subj":"1090","obj":"Gene:2213"},{"id":"A1091","pred":"pubann:denotes","subj":"1091","obj":"Gene:2213"},{"id":"A1094","pred":"pubann:denotes","subj":"1094","obj":"MESH:D010300"},{"id":"A1095","pred":"pubann:has_HGVS_notation","subj":"1095","obj":"p.E233P"},{"id":"A1096","pred":"pubann:has_HGVS_notation","subj":"1096","obj":"rs755807976"},{"id":"A1097","pred":"pubann:has_HGVS_notation","subj":"1097","obj":"p.L235A"},{"id":"A1098","pred":"pubann:has_HGVS_notation","subj":"1098","obj":"p.D265A"}],"text":"The IgG4 anti‐PD‐1 antibody tislelizumab has had its FcγR contact residues in the lower hinge E233, F234, L235 substituted with the equivalent residues of IgG2 P, V, A (E233P, F234V, L235A) as well as the additional D265A mutation which disrupts a major FcγR contact in CH2."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T303","span":{"begin":0,"end":274},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The IgG4 anti‐PD‐1 antibody tislelizumab has had its FcγR contact residues in the lower hinge E233, F234, L235 substituted with the equivalent residues of IgG2 P, V, A (E233P, F234V, L235A) as well as the additional D265A mutation which disrupts a major FcγR contact in CH2."}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T715","span":{"begin":14,"end":18},"obj":"Protein"}],"attributes":[{"id":"A715","pred":"uniprot_id","subj":"T715","obj":"https://www.uniprot.org/uniprot/Q7M4M5"},{"id":"A716","pred":"uniprot_id","subj":"T715","obj":"https://www.uniprot.org/uniprot/Q6NZ54"},{"id":"A717","pred":"uniprot_id","subj":"T715","obj":"https://www.uniprot.org/uniprot/Q3KQW2"},{"id":"A718","pred":"uniprot_id","subj":"T715","obj":"https://www.uniprot.org/uniprot/P18621"},{"id":"A719","pred":"uniprot_id","subj":"T715","obj":"https://www.uniprot.org/uniprot/J3QL51"},{"id":"A720","pred":"uniprot_id","subj":"T715","obj":"https://www.uniprot.org/uniprot/B5ME31"},{"id":"A721","pred":"uniprot_id","subj":"T715","obj":"https://www.uniprot.org/uniprot/B4E3C2"},{"id":"A722","pred":"uniprot_id","subj":"T715","obj":"https://www.uniprot.org/uniprot/B2R4H3"}],"text":"The IgG4 anti‐PD‐1 antibody tislelizumab has had its FcγR contact residues in the lower hinge E233, F234, L235 substituted with the equivalent residues of IgG2 P, V, A (E233P, F234V, L235A) as well as the additional D265A mutation which disrupts a major FcγR contact in CH2."}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T408","span":{"begin":19,"end":27},"obj":"Body_part"}],"attributes":[{"id":"A408","pred":"fma_id","subj":"T408","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"The IgG4 anti‐PD‐1 antibody tislelizumab has had its FcγR contact residues in the lower hinge E233, F234, L235 substituted with the equivalent residues of IgG2 P, V, A (E233P, F234V, L235A) as well as the additional D265A mutation which disrupts a major FcγR contact in CH2."}

{"project":"LitCovid-sentences","denotations":[{"id":"T303","span":{"begin":0,"end":274},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The IgG4 anti‐PD‐1 antibody tislelizumab has had its FcγR contact residues in the lower hinge E233, F234, L235 substituted with the equivalent residues of IgG2 P, V, A (E233P, F234V, L235A) as well as the additional D265A mutation which disrupts a major FcγR contact in CH2."}